DESTINY-Endometrial01 Phase 3 Trial Of ENHERTU® Initiated As First-Line Therapy In Patients With HER2 Expressing Primary Advanced Or Recurrent Endometrial Cancer

RefinitivThời gian đọc: dưới 1 phút

Daiichi Sankyo Co Ltd 4568:

DESTINY-ENDOMETRIAL01 PHASE 3 TRIAL OF ENHERTU® INITIATED AS FIRST-LINE THERAPY IN PATIENTS WITH HER2 EXPRESSING PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Đăng nhập hoặc tạo tài khoản miễn phí trọn đời để đọc tin tức này